文献速递核素与放射性配体治疗肿瘤 PET/CT

通过给予白蛋白结合抑制剂优化带白蛋白结合部分的211At标记RGD肽的药代动力学

Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-04

研究旨在通过竞争性抑制211At标记RGD肽与白蛋白结合来加速其血液清除。在正常小鼠中,注射后1小时给予不同摩尔当量的4-(4-碘苯基)丁酸钠(IPBA),血液放射性呈剂量依赖性降低。在U-87 MG荷瘤小鼠中,IPBA降低了血液和非靶组织放射性而不改变3小时肿瘤摄取,并显著抑制肿瘤生长。

要点

  • IPBA可剂量依赖性降低正常小鼠血液中211At标记RGD肽的放射性。
  • 荷瘤小鼠中IPBA降低血液和非靶组织摄取,3小时肿瘤摄取不变。
  • IPBA组较对照组显著抑制肿瘤生长。

核心结论

  • 给予白蛋白结合抑制剂IPBA可调节211At标记RGD肽的药代动力学并增强其治疗效果。

研究设计与样本

  • 在正常小鼠中评估不同剂量IPBA对211At标记RGD肽生物分布的影响,并在U-87 MG荷瘤小鼠中比较有无IPBA给药的生物分布、SPECT/CT显像和治疗效果。

主要发现

  • 正常小鼠中,注射211At标记RGD肽后1小时给予2、5或10摩尔当量(相对血白蛋白)的IPBA,血液放射性呈剂量依赖性降低。
  • U-87 MG荷瘤小鼠中,IPBA降低血液放射性和非靶组织累积,而注射后3小时肿瘤累积未改变。
  • 67Ga标记探针SPECT/CT显像中,IPBA给药大幅降低非靶组织放射性,仅肿瘤组织显影。
  • 治疗实验中,IPBA联合211At标记RGD肽组较对照组显著抑制肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A probe for targeted alpha therapy (TAT) using the RGD peptide (Ga-DOTA-K([211At]APBA)-c(RGDfK) ([211At]1)) with albumin-binding moiety (ABM) was recently developed. [211At]1 highly accumulated in tumors and significantly inhibited tumor growth in U-87 MG tumor-bearing mice. However, high [211At]1 retention in blood may cause critical adverse events, such as hematotoxicity. Therefore, we attempted to accelerate the blood clearance of [211At]1 by competitively inhibiting the binding of [211At]1 to albumin to modulate the pharmacokinetics of the former. METHODS: To evaluate the effects of albumin-binding inhibitors in normal mice, sodium 4-(4-iodophenyl)butanoate at 2, 5, or 10 molar equivalents of blood albumin was administered at 1-h postinjection of [211At]1. The biodistribution of [211At]1, SPECT/CT imaging of [67Ga]Ga-DOTA-K(IPBA)-c(RGDfK) ([67Ga]2), and the therapeutic effects of [211At]1 were compared with or without IPBA administration in U-87 MG tumor-bearing mice. RESULTS: Blood radioactivity of [211At]1 was decreased in a dose-dependent manner with IPBA in normal mice. In U-87 MG tumor-bearing mice, the blood radioactivity and accumulation in nontarget tissues of [211At]1 were decreased by IPBA. Meanwhile, tumor [211At]1 accumulation was not changed at 3-h postinjection of IPBA. In SPECT/CT imaging of [67Ga]2, IPBA administration dramatically decreased radioactivity in nontarget tissues, and only tumor tissue was visualized. In therapeutic experiments, [211At]1 with IPBA injected-group significantly inhibited tumor growth compared to the control group. CONCLUSION: IPBA administration (as an albumin-binding inhibitor) could modulate the pharmacokinetics and enhance the therapeutic effects of [211At]1.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Echigo H, Munekane M, Fuchigami T, et al. Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor. Eur J Nucl Med Mol Imaging. 2024. PMID: 38570359. doi:10.1007/s00259-024-06695-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。